Page 1

RACE ONCOLOGY 29 July 2021 + ASX Announcement June 2021 Quarterly Activity Report and Appendix 4C " Three Pillar " strategy progressed with two Phase 2 clinical programs underway for R / R AML in Israel & EMD AML in Australia Oversubscribed Placement of $ 5.4 million was successfully completed with existing shareholders rewarded via a Loyalty Bonus Option issue * Leadership team further strengthened with appointments of a Principal Scientist and a Chief Medical Officer , both of whom commenced in July 2021 Race makes continued progress on its Three Pillar strategy The June 2021 quarter ( Q4 FY 2021 ) was highlighted by the initiation of two clinical programs in Acute Myeloid Leukemia ( AML ) , the first being a Phase 2 combination drug study where Bisantrene will be trialled in patients with relapsed / refractory ( R / R ) AML . The study will be run in Israel led by Professor Anon Nagler who conducted the Bisantrene AML trial that reported in June 2020 , demonstrating an overall clinical response rate of 40 % ( ASX announcement : 16 June 2020 ) . Secondly , the Company signed an agreement with Parexel , a Clinical Research Organisation ( CRO ) to manage Race's Phase 2 AML program in Australia , focused on AML patients with the Extramedullary ( EMD ) form of the disease . No approved treatment options exist for EMD AML and this trial offers Bisantrene a pathway towards drug registration in an indication with large unmet clinical need . Progressing the Pillar 1 FTO - focussed program , Race announced an extensive pre - Clinical study in collaboration with research from the University of Newcastle to explore the use of Bisantrene in Melanoma and Kidney Cancer . These programs are progressing satisfactorily , and Race expects to provide updates over the remainder of CY 2021 . Bisantrene was further highlighted by the University of Chicago as a highly potent inhibitor of the FTO protein , confirming in an independent laboratory Bisantrene's ability to target FTO ( ASX announcement : 15 April 2021 ) . Our Phase 2 EMD AML trial includes a strata ( arm ) that uses low dose Bisantrene to target FTO in patients who cannot tolerate high intensity chemotherapy . Race successfully raised $ 5.4 million to support planned pre - clinical , clinical , and related manufacturing initiatives . In the quarter we recruited a Principal Scientist and a CMO to support the management of our growing clinical and pre - clinical programs . The expanded team is helping to progress the Three Pillar strategy , as Race makes concrete Race Oncology Ltd ABN 61 149 318 749 Registered office : L36 , 1 Macquarie Place , Sydney NSW 2000 www.raceoncology.com